References
- Akanuma Y., Kosaka K., Kuzuya T. Long term study of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus (in Japanese). Risho lyaku 1993; 9(suppl 3)127–49
- Ciaraldi T. P., Gilmore A., Olefsky J. M. In vitro studies on the action of CS-045 a new antidiabetic agent. Metabolism 1990; 39: 1056–62
- Claula A., Schwarz E. J., Dimaculangan D. D., Lazar M. A. Peroxisome proliferator-activited receptor (PPAR)γ: Adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135: 798–800
- Fujita T., Sugiyama Y., Taketomi S., Shoda T., Kawamatsu Y., Iwatsuka H., Suzuoki Z. Reduction of insulin resistance in obese and/or diabetic animals by 3 (-4-(1 methylcyclohexylmethoxy) benzyl-thiazolidine-2,4 dione) (ADD-3870, U-63287, ciglitazone), a new antidiabetic agent. Diabetes 1983; 32: 804–810
- Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of a new and antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1849–1888
- Issemarl. Green S. Activation of a member of the hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–680
- Iwamoto Y., Kosaka K., Kuzuya T. Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic Med. 1996; 13: 365–70
- Kawai K., Kawasaki-Tokui Y., Odaka T. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats mice and dogs. Arzneimittel Forschung 1997; 47: 356–8
- Khoursheed M., Miles P. D.G., Gao K. M., Lee M. K., Mossa A. R., Olefsky J. M. Metabolic effects of troglitazone on fat induced insulin resistance in the rat. Metabolism 1995; 44: 1489–1494
- Kuzuya T., Iwamoto Y., Kosaka K. An early phase II clinical trial of a new oral hypoglycemic drug, CS-045, in patients with non-insulin dependent diabetes meilitus (in Japanese). Rinsho lyaku 1993, Suppl. 3: 3–18
- Lee M. K., Miles P. D.G., Khoursheed M., Goa K. M., Mossa A. R., Olefsky J. M. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994; 43: 1435–1439
- Okuno Tamemoto H., Tobe K. The promotive effect of troglitazone, an insulin sensitizer, on differentiation of the adipose tissues in Zucker fatty rats [abst. 0329]. Diabetes 1997; 46(Suppl. 1)84A
- Shibita H., Nii S., Kobayashi M. Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers. Safety and pharmacokinetics in single administration [in Japanese]. Rinsho lyaku 1993; 9: 1503–18
- Shibukawa A., Sawada T., Nakao C. High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma. J. Chromatogr A. 1995; 697: 337–43
- Stevenson R. W., Hutson N. J., Krupp M. N., Volkmann R. A., Holland G. F., Eggler J. F., Clark D. A., McPherson R. K., Hell X. L., Danbury B. H. Actions of a novel antidiabetic agent englitazone inhyperglycemic hyperinsulinemic ob/ob mice. Diabetes 1990; 39: 1218–1227
- Stevenson R. W., McPherson R. K., McPherson R. K., Genereux B. E., Danbury B. H., Kreutter D. K. Antidiabetic agent Englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 1991; 40: 1268–1274
- Sunder R. M., Robert R. H. Strategies for preventing type II diabetes. Diabetes Prevention 1997; 101: 181–186
- Tominaga M., Igarashi M., Diamon M., Eguchi H., Matsumoto M., Sekikawa A., Yamatomi K., Sasaki H. Thiazolidinediones (AD-4533 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocrine J. 1993; 40: 343–349
- Tontonoz P., Hu E., Graves D. A., Budauon A. L., Speigelman B. M. mPPARγ2: tissue specific regulator of an adipocyte enhancer. Genes Dev. 1994; 8: 1224–1234